SYGNIS Further Strengthens its Patent Position for AX200 for the Treatment of Stroke
Complete the form below to unlock access to ALL audio articles.
SYGNIS Pharma AG, has announced that the European Patent Office has given two notices regarding their intention to issue additional AX200-patents shortly.
The respective patent applications cover the use of AX200 for the acute and chronic stage of a stroke. These additional patents will further strengthen SYGNIS’ patent portfolio of AX200 for the treatment of stroke which consists of six patent families.
The claims of the patent application for the treatment of acute stroke cover the actual use and dosage of AX200 as applied in the current Phase II efficacy study of AX200 (AXIS 2) and as intended to be used in clinical practice at a later stage.
With a scheduled expiry date of 2028, these claims complement the key patent granted in Europe in 2006 and in the USA in 2009, covering the use of AX200 for the treatment of stroke.
The claims of the second patent application cover the treatment of patients with AX200 in the chronic stage of a stroke. They have a scheduled expiry date of 2025 and complement SYGNIS’ IP-position in the early recovery phase following a stroke.
Dr. Frank Rathgeb, CMO of SYGNIS commented: “The granting of these patents will considerably strengthen the protection of our approaches for the treatment of stroke with AX200 as well as the actual therapeutic regimen for the acute treatment. Especially with regard to the top-line data of the AXIS 2-trial which we expect to report towards the end of this calendar year, this improved patent position will increase the overall value of the AX200 project and the awareness amongst potential partners.”
